Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Epidemiologic, clinical, and basic scientific studies led to an explosion in our understanding of disorders of mineral metabolism in the chronic kidney disease (CKD) patient. These advances are not always translated into improved care of renal osteodystrophy in CKD-5 patients. The introduction of a new class of drugs, calcimimetics, allows improved control of abnormal calcium/phosphorus metabolism. The calcimimetics compliment, rather than replace, current treatment options for secondary hyperparathyroidism in the chronic disease patient.
Lindberg
Jill S
JS
Metabolic & Stone Clinic, New Orleans Nephrology Associates, 4409 Utica Street, Ste. 100, Metairie, LA, USA. jlindberg@bellsouth.net
D000814:Aniline Compounds; D002118:Calcium / Q000819:agonists*; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000209:etiology; D000069449:Cinacalcet; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications*; D009281:Naphthalenes / Q000627:therapeutic use; D010627:Phenethylamines; D011437:Propylamines; D014807:Vitamin D / Q000627:therapeutic use
D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D009281:Naphthalenes; D010627:Phenethylamines; D011437:Propylamines; D014807:Vitamin D; D002118:Calcium; D000069449:Cinacalcet